- Home
- ELBM vs TCRX Comparison
ELBM vs TCRX Comparison
Compare ELBM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | TCRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 63.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELBM | TCRX |
|---|---|---|
| Price | $0.68 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.15 | ★ $7.00 |
| AVG Volume (30 Days) | 646.4K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.71 | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.50 | $0.88 |
| 52 Week High | $8.70 | $2.57 |
Technical Indicators
Market Signals| Indicator | ELBM | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 50.28 |
| Support Level | $0.50 | $0.90 |
| Resistance Level | $0.97 | $1.17 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 94.66 | 57.82 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.